Evidence map›Paper›PMID 33438349›Full record

ArticleThoracic cancer2021

In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy.

Lu Guo, Luyao Zhang, Yan Guan, Yan Li, Chufeng Zhang, Qisen Guo

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05481775 (Evaluating Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy Versus Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05481775 phase2withdrawnnot on this mapstarted 2022, after this paper: background citation

Evaluating Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy Versus Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer: A Prospective, Randomized Controlled Phase II Clinical Trial

TypeinterventionalSponsorSun Yat-sen UniversityRan2022 to 2025Enrolled0ConditionsLocally Advanced Non-small Cell Lung Cancer, Efficacy and SafetyArmsAnlotinib, Chemotherapy, Radiotherapy, Immunotherapy
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lu GuoShandong Cancer Hospital and Institute, Shandong University, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.ORCID 0000-0001-7361-3391
Luyao ZhangBreast and Thyroid Surgery, Affiliated Hospital of Weifang Medical University, Weifang, China.
Yan GuanShandong Cancer Hospital and Institute, Shandong University, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
Yan LiShandong Cancer Hospital and Institute, Shandong University, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
Chufeng ZhangShandong Cancer Hospital and Institute, Shandong University, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
Qisen GuoShandong Cancer Hospital and Institute, Shandong University, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
Shandong University · CNWeifang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo study in vitro the effects of anlotinib combined with radiotherapy on the lung cancer H520 cell cycle and apoptosis.

methodsThe log growth period H520 cells were divided into the control group, anlotinib group (A group), radiotherapy group (RT group) and combined group (A + RT group). Cell cycle and apoptosis were detected by flow cytometry and changes in H520 cell cycle and apoptosis were analyzed in each group.

resultsAnlotinib was determined to significantly inhibit cell growth in all groups, both alone, or in combination with radiotherapy. After receiving corresponding treatments, the proportions of G2/M-phase cells in the control group, A group, RT group and A + RT group were different, and statistically significant (F = 32.086, P < 0.001). The apoptotic cell statistics of H520 cells in the control group, A group, RT group and A + RT group were significantly different (F = 44.537, P < 0.01). The relative expression of CDK1 in each group of cells was 0.04 ± 0.02, 0.07 ± 0.12, 0.81 ± 0.11, and 0.56 ± 0.16, respectively. There were differences between the groups by analysis of variance which were statistically significant (F = 58.36, P < 0.0001). The relative expression of cycle B in each group of cells was 0.27 ± 0.05, 0.40 ± 0.16, 0.65 ± 0.14, and 0.57 ± 0.13, respectively. There were differences between the groups by analysis of variance which were statistically significant (F = 10.77, P = 0.0002).

conclusionsAnlotinib had an inhibitory effect on lung cancer H520 cell proliferation. A higher rate of apoptosis and G2/M phase block was observed in the anlotinib-radiotherapy combined group. Anlotinib combined with radiotherapy was able to synergistically inhibit tumor cell growth. KEY POINTS: Anrotinib combined with radiotherapy can synergistically inhibit tumor cell growth.

Indexed as

ApoptosisCell CycleHumansIndolesLung NeoplasmsQuinolinesanlotinibIndolesQuinolinesAnlotinibcell cycle/apoptosislung cancerradiotherapy

Identifiers

PMID33438349
PMCPMC7919126
OpenAlexW3120417767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.